Cargando…
XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer
Pancreatic ductal adenocarcinoma (PDAC) is associated with extensive dysregulation of the epigenome and epigenetic regulators, such as bromodomain and extraterminal motif (BET) proteins, have been suggested as potential targets for therapy. However, single-agent BET inhibition has shown poor efficac...
Autores principales: | Principe, Daniel R., Xiong, Rui, Li, Yangfeng, Pham, Thao N. D., Kamath, Suneel D., Dubrovskyi, Oleksii, Ratia, Kiira, Huang, Fei, Zhao, Jiong, Shen, Zhengnan, Thummuri, Dinesh, Daohong, Zhou, Underwood, Patrick W., Trevino, Jose, Munshi, Hidayatullah G., Thatcher, Gregory R. J., Rana, Ajay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795568/ https://www.ncbi.nlm.nih.gov/pubmed/35064087 http://dx.doi.org/10.1073/pnas.2116764119 |
Ejemplares similares
-
Alveolar soft part sarcoma mimics prostate cancer metastasis
por: Principe, Daniel R, et al.
Publicado: (2019) -
BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects
por: Abedin, Sameem M, et al.
Publicado: (2016) -
The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy
por: Principe, Daniel R., et al.
Publicado: (2021) -
Targeting BET bromodomain proteins in solid tumors
por: Sahai, Vaibhav, et al.
Publicado: (2016) -
Quercetin Enhances the Anti-Tumor Effects of BET Inhibitors by Suppressing hnRNPA1
por: Pham, Thao N.D., et al.
Publicado: (2019)